Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

Podjanee Jittamala; Simon Boyd; William HK Schilling; James A Watson; Thundon Ngamprasertchai; Tanaya Siripoon; Viravarn Luvira; Elizabeth M Batty; Phrutsamon Wongnak; Lisia M Esper; Pedro J Almeida; Cintia Cruz; Fernando R Ascencao; Renato S Aguiar; Najia K Ghanchi; James J Callery; Shivani Singh; Varaporn Kruabkontho; Thatsanun Ngernseng; Jaruwan Tubprasert; Wanassanan Madmanee; Kanokon Suwannasin; Amornrat Promsongsil; Borimas Hanboonkunupakarn; Kittiyod Poovorawan; Manus Potaporn; Attasit Srisubat; Bootsakorn Loharjun; Walter RJ Taylor; Farah Qamar; Abdul Momin Kazi; M. Asim Beg; Danoy Chommanam; Sisouphanh Vidhamaly; Kesinee Chotivanich; Mallika Imwong; Sasithon Pukrittayakamee; Arjen M Dondorp; Nicholas PJ Day; Mauro M Teixeira; Watcharapong Piyaphanee; Weerapong Phumratanaprapin; Nicholas J White; the PLATCOV Collaborative Group

doi:10.1101/2024.01.16.24301337

Data sharing statement

All code and de-identified participant data required for replication of the study’s endpoints are openly accessible via GitHub, as well as the study protocol and statistical analysis plan, from publication date onwards: https://github.com/jwatowatson/PLATCOV-Fluoxetine Individual Patient Data can be requested and may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future from the date of publication. Further information on how to apply is found here: https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing.